BRPI0417342A - fator estimulante de colÈnia de granulócitos glicopeguilado - Google Patents

fator estimulante de colÈnia de granulócitos glicopeguilado

Info

Publication number
BRPI0417342A
BRPI0417342A BRPI0417342-2A BRPI0417342A BRPI0417342A BR PI0417342 A BRPI0417342 A BR PI0417342A BR PI0417342 A BRPI0417342 A BR PI0417342A BR PI0417342 A BRPI0417342 A BR PI0417342A
Authority
BR
Brazil
Prior art keywords
conjugates
stimulating factor
colony stimulating
granulocyte colony
glycopeguylated
Prior art date
Application number
BRPI0417342-2A
Other languages
English (en)
Inventor
Shawn Defrees
Henrik Clausen
David A Zopf
Caryn Bowe
Mark Schwartz
Bingyuan Wu
Zhi-Guang Wang
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of BRPI0417342A publication Critical patent/BRPI0417342A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FATOR ESTIMULANTE DE COLÈNIA DE GRANULóCITOS GLICOPEGUILADO". A presente invenção fornece conjugados entre fator estimulante de colónia de granulócitos e porções de PEG. Os conjugados são ligados via um grupo de ligação de glicosil intacto que é interposto e covalentemente ligado ao peptídeo e o grupo de modificação. os conjugados são formados de peptídeos glicosilados e não glicosilados pela ação de uma glicosiltransferase. A glicosiltransferase liga uma porção de açúcar modificada em um aminoácido ou resíduo de glicosil no peptídeo. Também são fornecidas formulações farmacêuticas que incluem os conjugados. Métodos para a preparação dos conjugados também estão dentro do escopo da invenção.
BRPI0417342-2A 2003-12-03 2004-12-03 fator estimulante de colÈnia de granulócitos glicopeguilado BRPI0417342A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US52679603P 2003-12-03 2003-12-03
US53938704P 2004-01-26 2004-01-26
US55581304P 2004-03-23 2004-03-23
US57028204P 2004-05-11 2004-05-11
US59274404P 2004-07-29 2004-07-29
US61451804P 2004-09-29 2004-09-29
US62338704P 2004-10-29 2004-10-29
PCT/US2004/041004 WO2005055946A2 (en) 2003-12-03 2004-12-03 Glycopegylated granulocyte colony stimulating factor

Publications (1)

Publication Number Publication Date
BRPI0417342A true BRPI0417342A (pt) 2007-04-17

Family

ID=34682465

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417342-2A BRPI0417342A (pt) 2003-12-03 2004-12-03 fator estimulante de colÈnia de granulócitos glicopeguilado

Country Status (14)

Country Link
US (1) US20070254836A1 (pt)
EP (1) EP1694274B1 (pt)
JP (1) JP4657219B2 (pt)
KR (1) KR101237884B1 (pt)
CN (1) CN1897812B (pt)
AU (1) AU2004296855B2 (pt)
BR (1) BRPI0417342A (pt)
CA (1) CA2549409C (pt)
ES (1) ES2422187T3 (pt)
IL (1) IL175954A (pt)
MX (1) MXPA06006029A (pt)
NZ (1) NZ547554A (pt)
WO (1) WO2005055946A2 (pt)
ZA (1) ZA200604555B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
WO2007022512A2 (en) * 2005-08-19 2007-02-22 Neose Technologies, Inc. Glycopegylated factor vii and factor viia
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US7338933B2 (en) 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2043692B1 (en) 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
BRPI0717505B8 (pt) * 2006-10-04 2021-05-25 Novo Nordisk As conjugado de peptídeo e formulação farmacêutica
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
DK2197919T3 (da) 2007-08-27 2014-07-07 Ratiopharm Gmbh Flydende formulering af g-csf-konjugat
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
MX2010005291A (es) 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
JP5358840B2 (ja) * 2007-11-24 2013-12-04 独立行政法人産業技術総合研究所 Ｇｆｐ（緑色蛍光蛋白質）の機能賦活・回復方法
JP5225393B2 (ja) * 2008-02-18 2013-07-03 ジエンス ヘンルイ メデイシンカンパニー リミテッド 水溶性高分子修飾ｇ−ｃｓｆ複合体
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
RU2409669C9 (ru) 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
EP2330114B1 (en) * 2008-08-19 2017-08-16 Glytech, Inc. Glycoprotein production method and screening method
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
US8637640B2 (en) 2009-07-27 2014-01-28 Baxter International Inc. Blood coagulation protein conjugates
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
AU2011282571C1 (en) 2010-07-30 2018-04-05 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
PT2415779E (pt) * 2010-08-02 2015-05-13 Ratiopharm Gmbh Processo de produção e purificação de uma sialiltransferase solúvel activa
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
EP2714093A1 (en) 2011-05-27 2014-04-09 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
CN107043339B (zh) 2011-07-19 2019-09-06 希默赛生物技术有限责任公司 新交联试剂、大分子、治疗用偶联物及其合成方法
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP2018519359A (ja) * 2015-06-11 2018-07-19 アンビオ ファーマシューティカルズ，エルエルシー Ｐｅｇ化顆粒球コロニー刺激因子（ｇｃｓｆ）
MX2018006738A (es) 2015-12-03 2018-09-21 Baxalta Inc Factor viii con propiedades de semivida extendida y union reducida al ligando.

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH596313A5 (pt) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4385260A (en) * 1975-09-09 1983-05-24 Beckman Instruments, Inc. Bargraph display
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4565653A (en) * 1984-03-30 1986-01-21 Pfizer Inc. Acyltripeptide immunostimulants
JPS6238172A (ja) * 1985-08-12 1987-02-19 株式会社　高研 抗血栓性医用材料の製造方法
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
IL82834A (en) * 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5194376A (en) * 1989-02-28 1993-03-16 University Of Ottawa Baculovirus expression system capable of producing foreign gene proteins at high levels
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
DE4009630C2 (de) * 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US5951972A (en) * 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5858751A (en) * 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5202413A (en) * 1993-02-16 1993-04-13 E. I. Du Pont De Nemours And Company Alternating (ABA)N polylactide block copolymers
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5492841A (en) * 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5728554A (en) * 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US6030815A (en) * 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US5876980A (en) * 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5858752A (en) * 1995-06-07 1999-01-12 The General Hospital Corporation Fucosyltransferase genes and uses thereof
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
US5716812A (en) * 1995-12-12 1998-02-10 The University Of British Columbia Methods and compositions for synthesis of oligosaccharides, and the products formed thereby
WO1997032889A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of Michigan MURINE α(1,3)FUCOSYLTRANSFERASE Fuc-TVII, DNA ENCODING THE SAME, METHOD FOR PREPARING THE SAME, ANTIBODIES RECOGNIZING THE SAME, IMMUNOASSAYS FOR DETECTING THE SAME, PLASMIDS CONTAINING SUCH DNA, AND CELLS CONTAINING SUCH A PLASMID
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US20030027257A1 (en) * 1997-08-21 2003-02-06 University Technologies International, Inc. Sequences for improving the efficiency of secretion of non-secreted protein from mammalian and insect cells
EP0924298A1 (en) * 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
US6362254B2 (en) * 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
CA2324616A1 (en) * 1998-03-25 1999-09-30 Sloan-Kettering Institute For Cancer Research Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US6348558B1 (en) * 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
PT1259563E (pt) * 1999-12-22 2009-04-14 Nektar Therapeutics Al Corp Processo para a preparação de ésteres de 1-benzotriazolil- -carbonato de polímeros solúveis em água
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6570040B2 (en) * 2000-03-16 2003-05-27 The Regents Of The University Of California Chemoselective ligation
AU2001263149A1 (en) * 2000-05-12 2001-11-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
ATE468862T1 (de) * 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7297511B2 (en) * 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7696163B2 (en) * 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2042196B1 (en) * 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
AU2002351197A1 (en) * 2001-11-28 2003-06-10 Neose Technologies, Inc. Glycopeptide remodeling using amidases
US20060035224A1 (en) * 2002-03-21 2006-02-16 Johansen Jack T Purification methods for oligonucleotides and their analogs
EP1558728B1 (en) * 2002-11-08 2007-06-27 Glycozym ApS Methods to identify agents modulating functions of polypeptide galnac-transferases, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
US20050064540A1 (en) * 2002-11-27 2005-03-24 Defrees Shawn Ph.D Glycoprotein remodeling using endoglycanases
JP2006523211A (ja) * 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP1613261A4 (en) * 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
NZ542586A (en) * 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
AU2004240553A1 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) * 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US7338933B2 (en) * 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US20060024286A1 (en) * 2004-08-02 2006-02-02 Paul Glidden Variants of tRNA synthetase fragments and uses thereof
EP1799249A2 (en) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1797192A1 (en) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Modified proteins
WO2006066258A2 (en) * 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
JP2008526864A (ja) * 2005-01-06 2008-07-24 ネオス テクノロジーズ インコーポレイテッド 糖断片を用いる糖結合
EP1871795A4 (en) * 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007031559A2 (en) * 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
WO2007056191A2 (en) * 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
ITMI20061624A1 (it) * 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
ES2531934T3 (es) * 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
BRPI0717505B8 (pt) * 2006-10-04 2021-05-25 Novo Nordisk As conjugado de peptídeo e formulação farmacêutica
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides

Also Published As

Publication number Publication date
NZ547554A (en) 2009-09-25
HK1089685A1 (en) 2006-12-08
ES2422187T3 (es) 2013-09-09
CN1897812B (zh) 2011-08-17
EP1694274A2 (en) 2006-08-30
WO2005055946A2 (en) 2005-06-23
ZA200604555B (en) 2007-09-26
AU2004296855B2 (en) 2011-01-06
EP1694274B1 (en) 2013-04-24
CA2549409C (en) 2013-10-29
US20070254836A1 (en) 2007-11-01
IL175954A (en) 2014-06-30
CA2549409A1 (en) 2005-06-23
KR20070001890A (ko) 2007-01-04
AU2004296855A1 (en) 2005-06-23
JP4657219B2 (ja) 2011-03-23
JP2007513189A (ja) 2007-05-24
IL175954A0 (en) 2006-10-05
WO2005055946A3 (en) 2006-03-30
CN1897812A (zh) 2007-01-17
MXPA06006029A (es) 2006-08-23
EP1694274A4 (en) 2009-10-21
KR101237884B1 (ko) 2013-02-27

Similar Documents

Publication Publication Date Title
BRPI0614839A2 (pt) fator vii e fator viia glicopeguilados
BRPI0417341A (pt) fator ix glicopeguilado
Singh et al. Lectins from red algae and their biomedical potential
WO2005055946A3 (en) Glycopegylated granulocyte colony stimulating factor
US4980462A (en) Antiviral agents
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
Aoyagi et al. Fucosylation of serum α-fetoprotein in patients with primary hepatocellular carcinoma
ES2235330T3 (es) Analogos de saponionas triterpenicas que tienen actividad ayuvante.
ES2590679T3 (es) Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
CA2080502A1 (en) Method for producing synthetic n-linked glycoconjugates
BRPI0506741A (pt) glicosilação de peptìdeos ligados a o
ATE432288T1 (de) Neue interferon-beta-ähnliche moleküle
Shin et al. Chemoselective ligation of maleimidosugars to peptides/protein for the preparation of neoglycopeptides/neoglycoprotein
AU2009279090A1 (en) Conjugated proteins with prolonged in vivo efficacy
BRPI0511751A (pt) usos médicos de conjugados veìculos de peptìdeos de tnf não-humano
US11730786B2 (en) High molecular weight polysaccharide that binds and inhibits virus
ATE326478T1 (de) Peptidderivat
WO2005037210A3 (en) Photocleavable isotope-coded affinity tags
AU2025242163A1 (en) Saponin derivatives with improved therapeutic window
BR0208924A (pt) Uso de conjugados de ácido graxo de sal biliar ou de ácido biliar
BR0206852A (pt) Conjugados de polìmero de neublastina e métodos para uso dos mesmos
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
TWI634127B (zh) 糖鏈加成連接基、含有糖鏈加成連接基部分與生理活性物質部分之化合物或其鹽，及該等之製造方法
JP2010540488A (ja) 糖タンパク質及びグリコシル化細胞及びそれらの調製方法

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOGENERIX AG (DE)

Free format text: TRANSFERIDO DE: NEOSE TECHNOLOGIES, INC.

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL. A01N 43/04.

Ipc: A61K 38/22 (2006.01), A61P 31/00 (2006.01), A61P 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE SEU ARQUIVAMENTO DE ACORDO COM O ART. 34 DA LPI NOTIFICADO NA RPI NO 2220, DE 23/07/2013 (DESPACHO 11.5). TENDO EM VISTA O REQUERENTE TER ATENDIDO OS PRESSUPOSTOS DO ART. 34 DA LPI ATRAVES DA PETICAO NPRJ 020120040446 DE 08/05/2011 (DECLARACAO NEGATIVA), ANULO O REFERIDO ARQUIVAMENTO.

B25G Requested change of headquarter approved

Owner name: BIOGENERIX AG (DE)

B25D Requested change of name of applicant approved

Owner name: BIOGENERIX GMBH (DE)

B25A Requested transfer of rights approved

Owner name: RATIOPHARM GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL